CD14 and myeloid sarcoma: RR-MS patients with stable disease stage showed decreased frequencies of CD14+HLA-DRlow monocytic MDSCs and CD15+CD11b+HLA-DRlow granulocytic MDSCs compared to those during relapse (23).